Glaxo Group Limited

Christopher David Edlin

Paul Spencer Jones

Mika Lindvall

Martin Redpath Johnson

Caroline Mary Cook

Diane Mary Coe

Julie Nicole Hamblin

Charlotte Jane Mitchell

Anthony William James Cooper

Alison Judith Redgrave

David George Allen

Siegfried B Christensen, Iv

Michael D Dowle

Suzanne Elaine Keeling

Naimisha Trivedi

Lionel Trottet

John Edward Robinson

Caroline Jane Day

Stuart Holman

Leanda Jane Kindon

Reshma Manesh Chudasama

Amyn Pyarali Sayani

Rodger Phillip Barnett

Mika Kristian Lindvall

The invention provides N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl) (methyl)amino]octanoyl}amino)benzamide, whose formula is or a salt thereof, such as the monohydrochloride salt thereof. The invention also provides the use of the compound or salt as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, or rhinitis (e.g. allergic and/or non-allergic rhinitis).

Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors

The invention provides 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, which is the compound of formula (I): or a salt thereof.

Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor

The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Calkyl, Cfluoroalkyl or &#x2014;(CH)OH; Ris a hydrogen atom (H), methyl or Cfluoroalkyl; Ris a hydrogen atom (H) or Calkyl; Ris optionally substituted branched Calkyl, optionally substituted Ccycloalkyl, optionally substituted mono-unsaturated-Ccycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which nand nindependently are 1 or 2; and Y is O, S, SO, or NR; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors

The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Et, n-Pr, i-Pr, Cfluoroalkyl, or &#x2014;CHCHOH; wherein Ris methyl or ethyl; Ris H, methyl or ethyl; Ris H, methyl or ethyl, Ris H, methyl or ethyl, and Ris H or methyl, These compounds are PDE4 inhibitors.

[object Object]

Growing community of inventors

Stevenage, United Kingdom

Christopher David Edlin